— BMX —
A world leader in the field of in vitro diagnostics for 60 years, bioMérieux is present in 44 countries and serves more than 160 countries with the support of a large network of distributors.
bioMérieux provides diagnostic solutions (systems, reagents, software, services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases and some critical illnesses. Its diagnostic solutions are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on Euronext Paris stock market (Symbol: BIM – ISIN Code: FR0013280286).
Role within ImmunoSep
Within the ImmunoSep project, bioMérieux will actively participate in work packages 2, 3, 4 and 6. bioMérieux brings to the consortium knowledge on immune monitoring and patient stratification, clinical trial design and implementation (in particular by providing access to BioMérieux technologies and reagents, including on-going prototypes development). bioMérieux participates to the analysis of the multi-omics characterisation and provide industrial input on possible development path towards new diagnostics, including the theranostic approach.